KIF2C promotes the proliferation of hepatocellular carcinoma cells in vitro and in vivo Retraction in /10.3892/etm.2023.12095

Gao,Zhenya; Jia,Huanxia; Yu,Fang; Guo,Hongfang; Li,Baoyu

doi:10.3892/etm.2021.10528

KIF2C promotes the proliferation of hepatocellular carcinoma cells in vitro and in vivo

Retraction in: /10.3892/etm.2023.12095

Authors:
- Zhenya Gao
- Huanxia Jia
- Fang Yu
- Hongfang Guo
- Baoyu Li
View Affiliations

Affiliations: Department of Clinical Medicine, School of Medicine, Xuchang University, Xuchang, Henan 461000, P.R. China, Department of General Surgery, The Secondary Hospital of Tianjin Medical University, Tianjin 300211, P.R. China
Published online on: August 2, 2021 https://doi.org/10.3892/etm.2021.10528
Article Number: 1094
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies with high mortality and morbidity rates. In recent years, HCC targeted therapy has gained increasing attention. Due to the heterogeneity and high metastasis of HCC, more effective therapeutic targets are needed. Kinesin family member 2C (KIF2C), also known as mitotic centromere‑associated kinesin, is a microtubule‑based motor protein which is involved in a variety of important cellular processes, such as mitosis. The effects of KIF2C on cancer progression and development have been widely studied; however, its potential effects on HCC remains unclear. In the present study, high expression of KIF2C in human HCC tissues was demonstrated using The Cancer Genome Atlas database and immunohistochemistry assays. KIF2C expression was associated with HCC prognosis, including overall survival and disease‑free survival. KIF2C expression was also associated with clinical pathological characteristics including the number of tumor nodes (P=0.015) and tumor size (P=0.009). KIF2C knockdown inhibited the proliferation of HCC cells in vitro, confirmed by MTT and colony formation assays, and suppressed tumor growth in mice which was confirmed by a xenograft mouse model. Together, the results suggested that KIF2C may serve as a promising therapeutic target for the treatment of HCC.

View Figures

View References

1	Rahmani F, Ziaeemehr A, Shahidsales S, Gharib M, Khazaei M, Ferns GA, Ryzhikov M, Avan A and Hassanian SM: Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma. J Cell Physiol. 235:4146–4152. 2020.PubMed/NCBI View Article : Google Scholar
2	Ninio L, Nissani A, Meirson T, Domovitz T, Genna A, Twafra S, Srikanth KD, Dabour R, Avraham E, Davidovich A, et al: Hepatitis C virus enhances the invasiveness of hepatocellular carcinoma via egfr-mediated invadopodia formation and activation. Cells. 8(E1395)2019.PubMed/NCBI View Article : Google Scholar
3	Zhang Q, Chen W, Lv X, Weng Q, Chen M, Cui R, Liang G and Ji J: Piperlongumine, a novel TrxR1 inhibitor, induces apoptosis in hepatocellular carcinoma cells by ROS-mediated ER stress. Front Pharmacol. 10(1180)2019.PubMed/NCBI View Article : Google Scholar
4	Di Tommaso L, Spadaccini M, Donadon M, Personeni N, Elamin A, Aghemo A and Lleo A: Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol. 25:6041–6052. 2019.PubMed/NCBI View Article : Google Scholar
5	Wege H, Li J and Ittrich H: Treatment lines in hepatocellular carcinoma. Visc Med. 35:266–272. 2019.PubMed/NCBI View Article : Google Scholar
6	Choi SH and Seong J: Strategic application of radiotherapy for hepatocellular carcinoma. Clin Mol Hepatol. 24:114–134. 2018.PubMed/NCBI View Article : Google Scholar
7	Zhu XD and Sun HC: Emerging agents and regimens for hepatocellular carcinoma. J Hematol Oncol. 12(110)2019.PubMed/NCBI View Article : Google Scholar
8	Li L, Qian M, Chen IH, Finkelstein D, Onar-Thomas A, Johnson M, Calabrese C, Bahrami A, López-Terrada DH, Yang JJ, et al: Acquisition of cholangiocarcinoma traits during advanced hepatocellular carcinoma development in mice. Am J Pathol. 188:656–671. 2018.PubMed/NCBI View Article : Google Scholar
9	Manning AL, Ganem NJ, Bakhoum SF, Wagenbach M, Wordeman L and Compton DA: The kinesin-13 proteins Kif2a, Kif2b, and Kif2c/MCAK have distinct roles during mitosis in human cells. Mol Biol Cell. 18:2970–2979. 2007.PubMed/NCBI View Article : Google Scholar
10	Gwon MR, Cho JH and Kim JR: Mitotic centromere-associated kinase (MCAK/Kif2C) regulates cellular senescence in human primary cells through a p53-dependent pathway. FEBS Lett. 586:4148–4156. 2012.PubMed/NCBI View Article : Google Scholar
11	Bakhoum SF, Thompson SL, Manning AL and Compton DA: Genome stability is ensured by temporal control of kinetochore-microtubule dynamics. Nat Cell Biol. 11:27–35. 2009.PubMed/NCBI View Article : Google Scholar
12	Jiang K, Wang J, Liu J, Ward T, Wordeman L, Davidson A, Wang F and Yao X: TIP150 interacts with and targets MCAK at the microtubule plus ends. EMBO Rep. 10:857–865. 2009.PubMed/NCBI View Article : Google Scholar
13	Lee T, Langford KJ, Askham JM, Brüning-Richardson A and Morrison EE: MCAK associates with EB1. Oncogene. 27:2494–2500. 2008.PubMed/NCBI View Article : Google Scholar
14	Vogt E, Sanhaji M, Klein W, Seidel T, Wordeman L and Eichenlaub-Ritter U: MCAK is present at centromeres, midspindle and chiasmata and involved in silencing of the spindle assembly checkpoint in mammalian oocytes. Mol Hum Reprod. 16:665–684. 2010.PubMed/NCBI View Article : Google Scholar
15	Shao H, Huang Y, Zhang L, Yuan K, Chu Y, Dou Z, Jin C, Garcia-Barrio M, Liu X and Yao X: Spatiotemporal dynamics of Aurora B-PLK1-MCAK signaling axis orchestrates kinetochore bi-orientation and faithful chromosome segregation. Sci Rep. 5(12204)2015.PubMed/NCBI View Article : Google Scholar
16	Jang CY and Fang G: DDA3 associates with MCAK and controls chromosome congression. Biochem Biophys Res Commun. 407:610–614. 2011.PubMed/NCBI View Article : Google Scholar
17	Parra MT, Gómez R, Viera A, Page J, Calvente A, Wordeman L, Rufas JS and Suja JA: A perikinetochoric ring defined by MCAK and Aurora-B as a novel centromere domain. PLoS Genet. 2(e84)2006.PubMed/NCBI View Article : Google Scholar
18	Gan H, Lin L, Hu N, Yang Y, Gao Y, Pei Y, Chen K and Sun B: KIF2C exerts an oncogenic role in nonsmall cell lung cancer and is negatively regulated by miR-325-3p. Cell Biochem Funct. 37:424–431. 2019.PubMed/NCBI View Article : Google Scholar
19	Gnjatic S, Cao Y, Reichelt U, Yekebas EF, Nölker C, Marx AH, Erbersdobler A, Nishikawa H, Hildebrandt Y, Bartels K, et al: NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. Int J Cancer. 127:381–393. 2010.PubMed/NCBI View Article : Google Scholar
20	Bai Y, Xiong L, Zhu M, Yang Z, Zhao J and Tang H: Co-expression network analysis identified KIF2C in association with progression and prognosis in lung adenocarcinoma. Cancer Biomark. 24:371–382. 2019.PubMed/NCBI View Article : Google Scholar
21	Bie L, Zhao G, Wang YP and Zhang B: Kinesin family member 2C (KIF2C/MCAK) is a novel marker for prognosis in human gliomas. Clin Neurol Neurosurg. 114:356–360. 2012.PubMed/NCBI View Article : Google Scholar
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
23	Pinato DJ, Mauri FA, Spina P, Cain O, Siddique A, Goldin R, Victor S, Pizio C, Akarca AU, Boldorini RL, et al: Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: The Blueprint-HCC study. Br J Cancer. 120:1033–1036. 2019.PubMed/NCBI View Article : Google Scholar
24	Ishikawa T: Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 19:8861–8866. 2013.PubMed/NCBI View Article : Google Scholar
25	Banini BA and Sanyal AJ: The use of cell free DNA in the diagnosis of HCC. Hepatoma Res. 5(34)2019.PubMed/NCBI View Article : Google Scholar
26	Yang Y, Zhao Z, Xie C and Zhao Y: Dual-targeting liposome modified by glutamic hexapeptide and folic acid for bone metastatic breast cancer. Chem Phys Lipids. 228(104882)2020.PubMed/NCBI View Article : Google Scholar
27	Zhao Z, Zhao Y, Xie C, Chen C, Lin D, Wang S, Lin D, Cui X, Guo Z and Zhou J: Dual-active targeting liposomes drug delivery system for bone metastatic breast cancer: Synthesis and biological evaluation. Chem Phys Lipids. 223(104785)2019.PubMed/NCBI View Article : Google Scholar
28	Hasan S, Abel S, Uemura T, Verma V, Koay EJ, Herman J, Thai N and Kirichenko A: Liver transplant mortality and morbidity following preoperative radiotherapy for hepatocellular carcinoma. HPB (Oxford). 22:770–778. 2020.PubMed/NCBI View Article : Google Scholar
29	Shimo A, Tanikawa C, Nishidate T, Lin ML, Matsuda K, Park JH, Ueki T, Ohta T, Hirata K, Fukuda M, et al: Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis. Cancer Sci. 99:62–70. 2008.PubMed/NCBI View Article : Google Scholar
30	Sanhaji M, Friel CT, Wordeman L, Louwen F and Yuan J: Mitotic centromere-associated kinesin (MCAK): A potential cancer drug target. Oncotarget. 2:935–947. 2011.PubMed/NCBI View Article : Google Scholar
31	Li C, Zhang Y, Yang Q, Ye F, Sun SY, Chen ES and Liou YC: NuSAP modulates the dynamics of kinetochore microtubules by attenuating MCAK depolymerisation activity. Sci Rep. 6(18773)2016.PubMed/NCBI View Article : Google Scholar
32	Ritter A, Kreis NN, Louwen F, Wordeman L and Yuan J: Molecular insight into the regulation and function of MCAK. Crit Rev Biochem Mol Biol. 51:228–245. 2015.PubMed/NCBI View Article : Google Scholar
33	Wang W, Shen T, Guerois R, Zhang F, Kuerban H, Lv Y, Gigant B, Knossow M and Wang C: New Insights into the Coupling between Microtubule Depolymerization and ATP Hydrolysis by Kinesin-13 Protein Kif2C. J Biol Chem. 290:18721–18731. 2015.PubMed/NCBI View Article : Google Scholar
34	Zhang GP, Shen SL, Yu Y, Yue X, Hu WJ and Li SQ: Kinesin family member 2C aggravates the progression of hepatocellular carcinoma and interacts with competing endogenous RNA. J Cell Biochem. 121:4419–4430. 2020.PubMed/NCBI View Article : Google Scholar
35	Rath O and Kozielski F: Kinesins and cancer. Nat Rev Cancer. 12:527–539. 2012.PubMed/NCBI View Article : Google Scholar
36	Wojcik EJ, Buckley RS, Richard J, Liu L, Huckaba TM and Kim S: Kinesin-5: Cross-bridging mechanism to targeted clinical therapy. Gene. 531:133–149. 2013.PubMed/NCBI View Article : Google Scholar